Personalized Cancer Vaccine Keeps Melanoma from Returning

Over 1,000 people with high-risk melanoma just stayed cancer-free longer thanks to a vaccine custom-built from their own tumors.

Drug companies Moderna and Merck announced results from a phase three trial testing a personalized cancer vaccine called Intismeran. Patients received the vaccine alongside Keytruda, an immunotherapy drug already used in cancer treatment, after having surgery to remove their melanoma.

The combination worked significantly better than Keytruda alone. It extended the time patients remained cancer-free and reduced the risk of the disease spreading to other organs.

Here's what makes this vaccine different. Scientists remove a small piece of each patient's tumor and sequence its DNA to identify the cancer's unique mutations. Then they use mRNA technology to create a personalized shot that trains that specific patient's immune system to hunt down any remaining cancer cells with those exact mutations.

The same mRNA technology that helped create some COVID-19 vaccines now gives doctors a powerful new tool against cancer. Each vaccine is literally one of a kind, designed for one person's tumor.

The trial included patients with stage two, three, or four melanoma, ranging from large localized tumors to cancers that had already spread to other parts of the body. That means the treatment showed promise even in more advanced cases.

Moderna CEO Stephane Bancel called the findings a "pivotal moment" in cancer research. Shares in both companies surged following the announcement, reflecting investor confidence in the approach.

The Ripple Effect

Both companies are already testing similar personalized vaccines for lung, bladder, and kidney cancers. If those trials succeed, this approach could transform treatment for multiple cancer types.

Dr. Lennard Lee, a medical oncologist at the University of Oxford, emphasized the broader significance beyond melanoma. "It provides proof of principle that personalized cancer vaccines work," he said.

Cancer Research UK's Dr. Talisia Quallo called the research promising while noting the interim data still needs full review and peer examination by independent experts. The treatment would also need regulatory approval before becoming available through health systems like the NHS.

The trial results offer hope that cancer treatment is entering a new era where vaccines can be tailored to each person's unique disease, turning the immune system into a precision weapon against tumors.